Savara (SVRA) Tops Q1 EPS by 3c

Savara (NASDAQ: SVRA) reported Q1 EPS of ($0.34), $0.03 better than the analyst estimate of ($0.37).

“We are diligently preparing for the highly anticipated readout of our Phase 3 IMPALA study in June, which we expect to be followed by the submission of a Biologics License Application in the first half of 2020 and, if approved, a commercial launch of Molgradex later in 2020 or early 2021,” said Rob Neville, Chief Executive Officer, Savara. “These pivotal results could be transformational for the Company and, more importantly, for patients with aPAP, a rare and progressive lung disease. Our commitment to improving the lives of people with orphan lung diseases, and accelerating the advancement of our innovative therapies, is unwavering. With multiple catalysts expected over the coming quarters, we are well positioned for sustained growth.”

For earnings history and earnings-related data on Savara (SVRA) click here.

You May Also Be Interested In

• Primoris cuts 2026 outlook on renewables cost overruns, COO exits
• Gil Issachar steps down as CTO at Firefly Neuroscience
• Comfort Systems USA names new COO and Chief Strategy Officer